Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

PUBLICATION DATE

11 results
Display

The 5th Biennial Meeting of the Asian Society of Gynecologic Oncology, November 30th to December 2nd, 2017

Tominaga E, Kobayashi , Aoki D

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer

Mikami M, Shida M, Shibata T, Katabuchi , Kigawa J, Aoki D, Yaegashi N

OBJECTIVE: The Japan Society of Gynecologic Oncology (JSGO) initiated a nation-wide training system for the education and certification for gynecologic oncologists in 2005. To assess the impact of the quality...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Trends of uterine carcinosarcoma in the United States

Matsuo K, Ross MS, Machida H, Blake EA, Roman LD

OBJECTIVE: Uterine carcinosarcoma (UCS) is a rare type of high-grade endometrial cancer (EC) that has been understudied with population-based statistics due to its rarity. This study examined temporal trends in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Major clinical research advances in gynecologic cancer in 2017

Suh DH, Kim M, Lee KH, Eom KY, Kjeldsen M, Mirza MR, Kim JW

In 2017, 10 topics were selected as major clinical research advances in gynecologic oncology. For cervical cancer, efficacy and safety analysis results of a 9-valent human papillomavirus (HPV) vaccine and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism

Li SS, Ma J, Wong AS

Ovarian cancer is most deadly gynecologic malignancies worldwide. Chemotherapy is the mainstay treatment for ovarian cancer. Despite the initial response is promising, frequent recurrence in patients with advanced diseases remains...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Trends in single women with malignancy of the uterine cervix in United States

Machida H, Blake EA, Eckhardt S, Takiuchi T, Grubbs BH, Mikami M, Roman LD, Matsuo K

OBJECTIVE: To examine trends and characteristics of single women with malignancy of the uterine cervix. METHODS: This is a retrospective observational study examining the United States population-based tumor registry (the Surveillance,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma

Yamazaki H, Todo Y, Shimada C, Takeshita , Minobe S, Okamoto K, Yamashiro , Kato H

OBJECTIVES: This study evaluated the therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma (OCCC). METHODS: We retrospectively reviewed records of 127 consecutive patients with pT1/pT2 and M0 OCCC...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Seromucinous component in endometrioid endometrial carcinoma as a histological predictor of prognosis

Miyamoto M, Takano M, Aoyama T, Soyama H, Yoshikawa , Tsuda H, Furuya K

OBJECTIVE: In 2014 World Health Organization criteria, seromucinous carcinoma was defined as a new histological subtype in ovarian carcinomas, but “seromucinous carcinoma” was not defined in endometrial carcinomas. The aim...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of adjuvant hysterectomy on prognosis in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy: a meta-analysis

Shim SH, Kim SN, Chae SH, Kim JE, Lee SJ

OBJECTIVE: Few data exist regarding adjuvant hysterectomy (AH) in locally advanced cervical cancer (LACC) patients treated with chemoradiotherapy. We investigated the effect of AH on prognosis in LACC patients, through...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis

Paik ES, Kim TJ, Choi CH, Kim BG, Bae DS, Lee JW

OBJECTIVE: The aim of this investigation is to compare outcomes of patients according to the presence of cancer arising from endometriosis in ovarian clear cell carcinoma (CCC) and endometrioid carcinoma...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?

Yamagami W, Susumu N, Makabe T, Sakai K, Nomura H, Kataoka F, Hirasawa A, Banno K, Aoki D

OBJECTIVE: Reports on the repeated administration of medroxyprogesterone acetate (MPA) for intrauterine recurrence after fertility-preserving therapy for atypical endometrial hyperplasia (AEH) and early grade 1 endometrioid carcinoma (G1) are lacking....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr